Monte Rosa Therapeutics, Inc. (GLUE)Healthcare | Biotechnology | Boston, United States | NasdaqGS
21.98 USD
-1.06
(-4.601%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 2:38 a.m. EDT
The fundamental reality here is stark: Monte Rosa Therapeutics is a deep-value trap in disguise. The company is hemorrhaging cash, with revenue collapsing by 95% year-over-year and gross margins in negative territory. Despite the 'strong buy' analyst consensus, which likely stems from a single potential catalyst, the balance sheet is fragile with negative free cash flow and no earnings visibility. The stock has already punished investors severely, dropping nearly 73% over the last four years, though it recently staged a technical recovery off its lows. The short-term outlook remains murky. While the price has bounced off the $4 support level, the lack of a clear catalyst makes any rally a gamble. The options market confirms this uncertainty, with heavy betting on both sides implying a binary event is needed to drive the next leg. Without a confirmed clinical success or partnership deal, the risk of further dilution or cash burn outweighs the speculative upside. For now, the thesis is neutral-to-bearish until a definitive catalyst materializes. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.116565 |
| AutoETS | 0.121524 |
| AutoARIMA | 0.121524 |
| AutoTheta | 0.121837 |
| MSTL_74 | 0.129452 |
Forecast horizon: 60 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 4.11 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.088 |
| Excess Kurtosis | -0.23 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 7.485 |
| Revenue per Share | 0.491 |
| Market Cap | 1,856,857,472 |
| Forward P/E | -12.11 |
| Beta | 1.56 |
| Website | https://www.monterosatx.com |
As of July 11, 2026, 2:38 a.m. EDT: Speculators are positioning for significant volatility rather than a specific directional breakout. Call open interest is heavily skewed toward out-of-the-money strikes ($25, $30, $35), suggesting a speculative bet on a sharp rally or biotech catalyst. However, put open interest is even more aggressive, with massive concentrations at lower strikes ($15, $17.50, $20) and notably higher implied volatility than calls. This 'straddle' style positioning indicates traders expect a binary event—either a major clinical readout or a regulatory decision—that could swing the price wildly in either direction, rather than a steady grind higher.
| Attribute | Value |
|---|---|
| 52 Week Change | 3.380228 |
| Address1 | 321 Harrison Avenue |
| Address2 | Suite 900 |
| All Time High | 45.56 |
| All Time Low | 2.44 |
| Ask | 27.17 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,985,110 |
| Average Daily Volume3 Month | 1,151,511 |
| Average Volume | 1,151,511 |
| Average Volume10Days | 1,985,110 |
| Beta | 1.562 |
| Bid | 16.17 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 6.19 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 21.98 |
| Current Ratio | 9.538 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 23.05 |
| Day Low | 20.925 |
| Debt To Equity | 7.485 |
| Display Name | Monte Rosa Therapeutics |
| Earnings Timestamp | 1,778,157,000 |
| Earnings Timestamp End | 1,786,019,400 |
| Earnings Timestamp Start | 1,786,019,400 |
| Ebitda | -139,940,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -8.787 |
| Enterprise To Revenue | 28.629 |
| Enterprise Value | 1,229,701,632 |
| Eps Current Year | -1.59143 |
| Eps Forward | -1.81429 |
| Eps Trailing Twelve Months | -1.41 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 19.7263 |
| Fifty Day Average Change | 2.2537003 |
| Fifty Day Average Change Percent | 0.11424851 |
| Fifty Two Week Change Percent | 338.0228 |
| Fifty Two Week High | 25.77 |
| Fifty Two Week High Change | -3.790001 |
| Fifty Two Week High Change Percent | -0.14707027 |
| Fifty Two Week Low | 4.12 |
| Fifty Two Week Low Change | 17.86 |
| Fifty Two Week Low Change Percent | 4.334952 |
| Fifty Two Week Range | 4.12 - 25.77 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,624,541,400,000 |
| Float Shares | 49,578,436 |
| Forward Eps | -1.81429 |
| Forward P E | -12.114931 |
| Free Cashflow | -61,151,752 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 187 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | -2.3853998 |
| Gross Profits | -102,460,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0057800002 |
| Held Percent Institutions | 1.1322 |
| Implied Shares Outstanding | 84,479,418 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-06-24 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts. |
| Long Name | Monte Rosa Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 1,856,857,472 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_690261281 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -130,014,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,856,012,813 |
| Number Of Analyst Opinions | 6 |
| Open | 22.69 |
| Operating Cashflow | -14,675,000 |
| Operating Margins | -11.884561 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 617 949 2643 |
| Pre Market Change | 0.37000084 |
| Pre Market Change Percent | 1.6833524 |
| Pre Market Price | 22.35 |
| Pre Market Time | 1,784,028,911 |
| Previous Close | 23.04 |
| Price Eps Current Year | -13.811478 |
| Price Hint | 2 |
| Price To Book | 3.5508885 |
| Price To Sales Trailing12 Months | 43.229984 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.444 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | -1.06 |
| Regular Market Change Percent | -4.6007 |
| Regular Market Day High | 23.05 |
| Regular Market Day Low | 20.925 |
| Regular Market Day Range | 20.925 - 23.05 |
| Regular Market Open | 22.69 |
| Regular Market Previous Close | 23.04 |
| Regular Market Price | 21.98 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,556,411 |
| Return On Assets | -0.16408001 |
| Return On Equity | -0.32623002 |
| Revenue Growth | -0.95 |
| Revenue Per Share | 0.491 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 84,479,418 |
| Shares Percent Shares Out | 0.2206 |
| Shares Short | 18,634,735 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 16,005,122 |
| Short Name | Monte Rosa Therapeutics, Inc. |
| Short Percent Of Float | 0.2241 |
| Short Ratio | 11.61 |
| Source Interval | 15 |
| State | MA |
| Symbol | GLUE |
| Target High Price | 37.0 |
| Target Low Price | 29.0 |
| Target Mean Price | 33.16667 |
| Target Median Price | 33.0 |
| Total Cash | 666,220,032 |
| Total Cash Per Share | 7.886 |
| Total Debt | 39,064,000 |
| Total Revenue | 42,953,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.41 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 17.048325 |
| Two Hundred Day Average Change | 4.931675 |
| Two Hundred Day Average Change Percent | 0.2892762 |
| Type Disp | Equity |
| Volume | 1,556,411 |
| Website | https://www.monterosatx.com |
| Zip | 2,118 |